Company intelligence / Profile preview

Genis

Ownership: Private
Development stage: Preclinical

Overview

Genis is pioneering the use of therapeutic chitin derivatives for pharmaceutical applications in inflammatory diseases and orthobiologic medical devices. The company has invested approximately $40M USD in R&D over two decades, with a robust IP portfolio. Their lead science focuses on the anti-inflammatory properties of chitooligosaccharides and the regenerative/antibacterial properties of their proprietary ChitoBiomer for bone implants. Clinical results are not yet published or available as of now; programs appear to be preclinical or early-stage.

Therapeutic areas: PulmonologyRheumatologyImmunology
Modalities: Chitin derivatives (including chitooligosaccharides and ChitoBiomer)
Industry: Biotech

Drug pipeline

2 assets

Benecta

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Genis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genis.

Explore the full profile